id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
CDC-2018-0004-0064,CDC,CDC-2018-0004,NIOSH Response to Peer Review comments,Supporting & Related Material,,2018-05-03T04:00:00Z,2018,5,,,2018-05-03T12:44:48Z,,0,0,0900006483226628
CDC-2018-0004-0019,CDC,CDC-2018-0004,2018 Stakeholder Review Summaries,Supporting & Related Material,,2018-04-13T04:00:00Z,2018,4,,,2018-04-13T18:43:46Z,,0,0,090000648313c844
CDC-2018-0004-0009,CDC,CDC-2018-0004,General question for the record,Other,,2018-03-28T04:00:00Z,2018,3,2018-03-28T04:00:00Z,,2018-03-28T12:18:17Z,,0,0,0900006483058d23
CDC-2018-0004-0002,CDC,CDC-2018-0004,Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs In Healthcare Settings,Supporting & Related Material,,2018-02-14T05:00:00Z,2018,2,,,2018-02-14T11:54:11Z,,0,0,0900006482f07ec2
CDC-2018-0004-0003,CDC,CDC-2018-0004,"Table 4, excerpted from Federal Register notice NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings:  Proposed Additions to the NIOSH Hazardous Drug List 2018",Supporting & Related Material,,2018-02-14T05:00:00Z,2018,2,,,2018-02-14T11:59:16Z,,0,0,0900006482f2f887
CDC-2018-0004-0001,CDC,CDC-2018-0004,NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings:  Proposed Additions to the NIOSH Hazardous Drug List 2018,Notice,,2018-02-14T05:00:00Z,2018,2,2018-02-14T05:00:00Z,2018-04-17T03:59:59Z,2018-04-19T01:04:24Z,2018-02957,0,0,0900006482f2df44